Artificial human livers engineered for drug testing and discovery

March 15, 2013, Agency for Science, Technology and Research (A*STAR), Singapore

The liver is an important target organ for drug testing because all drugs pass through it for detoxification. This is a process whereby harmful substances are reduced or removed from the body. Drugs that cannot be detoxified may cause poisoning or other lethal side effects. IBN researchers have now made it possible for companies to predict the toxicity of new drugs earlier, potentially speeding up the drug development process and reducing the cost of manufacturing. The tool they have engineered to enable this is an artificial human liver piece, which mimics the natural tissue environment closely.

IBN Executive Director Professor Jackie Y. Ying, said, "This research advance is the first testing model available that can sensitively predict long-term in the liver. Such predictive toxicology platforms are useful research tools that aid and accelerate the discovery of . The ability to determine drug toxicity at an early stage would lead to significant cost savings for the pharmaceutical companies and consumers."

IBN Group Leader Professor Hanry Yu elaborated, "Most materials and devices have been designed with little attention to what the cells need. By using a cell-centered approach and translating our basic understanding of tissue behavior, we have developed liver that can simulate conditions outside the body with striking similarity to organs inside the body."

IBN's liver tissue models for drug toxicity testing comprise the following patented technologies:

  • Three-dimensional cellulosic scaffold. Using hydroxypropyl cellulose, an FDA-approved plant-based material that is the basic building block of cotton and paper, IBN fabricated a biocompatible porous scaffold that enables to spontaneously assemble into three-dimensional liver spheroids. These spheroids strongly resemble liver tissue, hence facilitating . This technology was licensed in 2010 to Bio-Byblos Biomedical Co. Ltd, a biomedical company based in Taiwan, for manufacturing.
  • Liver-on-chip. IBN's innovative HepaTox chip is a 'liver-on-chip' that allows researchers to test the effect of drugs on the liver. By seeding liver cells within a microfluidic system, the micro device is used to screen the liver's capacity to process different drugs and other compounds. The HepaTox chip features eight channels, which enable multiple drug screening in parallel. With miniaturization, the amount of liver cells and drugs can also be significantly reduced, saving cost without comprising efficiency. This breakthrough technology has been published in peer-reviewed journal Lab on a Chip, 7 (2007) 302-309, and is one of the journal's most downloaded papers.
  • Microporous membrane sandwich culture. A typical drug screening platform requires liver cells for testing, and conventionally the cells are cultured within a collagen-based gel. However, the gel can trap drugs and limit access to nutrients and oxygen, leading to variable and inconsistent results. Using IBN's microfabricated microporous membrane, the liver cells are sandwiched between the membranes, which can control the transfer of drugs, nutrients and oxygen to the cells, and provide more reliable and reproducible screening results. The membrane surface has been engineered to simulate liver cell interaction with matrix and promote formation of liver tissues after the cells are seeded. Experiments have shown that the microporous membranes can maintain long-term liver cell functions for more than two weeks and will be useful for chronic liver toxicity testing, and industry-scale drug screening.
If commercialized, IBN's liver tissue models can be developed into test kits to support drug development and pre-clinical research. In January this year, IBN collaborated with Janssen, a pharmaceutical company of Johnson & Johnson, to produce liver cells from human stem cells for drug testing. This new research project leverages on IBN's expertise in engineering to develop an alternative source of human liver cells that are limited in supply. IBN is also working with global healthcare company Hoffman La-Roche on a new drug screening method for hepatitis viruses, which are leading causes of cancer.

Explore further: Mice with human livers make pharmaceutical testing more accurate

More information: Coupled with IBN's expertise in nephrotoxicology that was recently published in Kidney International, (2013) DOI: 10.1038/ki.2012.442, the Institute can now facilitate drug toxicity testing for both the liver and the kidney, offering an inexpensive alternative to animal testing.

Related Stories

Mice with human livers make pharmaceutical testing more accurate

July 12, 2011
(Medical Xpress) -- In a new report published in the Proceedings of the National Academy of Sciences, a team of researchers reveal a new miniature artificial human liver that can be implanted into mice to better enable testing ...

Artificial liver to replace animal testing, potential to accelerate development of new drugs

November 13, 2012
Scientists at Heriot-Watt University are working towards creating the world's first artificial human livers for drug testing to drastically cut the number of live animals used and get life-saving medicines into the clinic ...

Restoring what's lost: Uncovering how liver tissue regenerates

March 12, 2012
The liver is unique among mammalian organs in its ability to regenerate after significant tissue damage or even partial surgical removal.

Unlimited source of human kidney cells: Applications include in vitro toxicology, disease models, regenerative medicine

February 21, 2013
Researchers at the Institute of Bioengineering and Nanotechnology (IBN) have successfully generated human kidney cells from human embryonic stem cells in vitro. Specifically, they produced the renal cells under artificial ...

Creating precursor liver cells from stem cells

June 8, 2011
(Medical Xpress) -- Scientists from the Departments of Biology & Biochemistry and Pharmacy & Pharmacology have discovered a new way to create precursor liver cells from stem cells, with the potential to impact on the testing ...

Recommended for you

Switch discovered to convert blood vessels to blood stem cells in embryonic development

March 20, 2018
A switch has been discovered that instructs blood vessel cells to become blood stem cells during embryonic development in mice. Using single-cell technology, researchers from the Wellcome Sanger Institute in Cambridge and ...

Scientists discover new causes of cellular decline in prematurely aging kids

March 19, 2018
In a recent paper published in Cell Reports, Saint Louis University researchers have uncovered new answers about why cells rapidly age in children with a rare and fatal disease. The data points to cellular replication stress ...

Don't blame adolescent social behavior on hormones

March 19, 2018
Reproductive hormones that develop during puberty are not responsible for changes in social behavior that occur during adolescence, according to the results of a newly published study by a University at Buffalo researcher.

Stem cells treat macular degeneration

March 19, 2018
In July 2015, 86-year-old Douglas Waters developed severe age-related macular degeneration (AMD). He struggled to see things clearly, even when up close.

Measuring neutrophil motility could lead to accurate sepsis diagnosis

March 19, 2018
A microfluidic device developed by Massachusetts General Hospital (MGH) investigators may help solve a significant and persistent challenge in medicine—diagnosing the life-threatening complication of sepsis. In their paper ...

Democratizing science: Researchers make neuroscience experiments easier to share, reproduce

March 16, 2018
Over the past few years, scientists have faced a problem: They often cannot reproduce the results of experiments done by themselves or their peers.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.